Development of positron emission tomography probe of 64Cu-labeled anti-C-kit 12A8 Fab to measure protooncogene C-kit expression

Nuclear Medicine and Biology

Volumn 38, Issue 3, 2011, Pages 331-337

  Yoshida, Chisato ^a,b   Tsuji, Atsushi B ^a   Sudo, Hitomi ^a   Sugyo, Aya ^a   Sogawa, Chizuru ^a   Inubushi, Masayuki ^a   Uehara, Tomoya ^b   Fukumura, Toshimitsu ^a   Koizumi, Mitsuru ^a   Arano, Yasushi ^b   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

64Cu; Antibody; C kit; Noninvasive imaging; Positron emission tomography; Tumor

Indexed keywords

COPPER MONOCLONAL ANTIBODY 12A8 FAB FRAGMENT CU 64; INDIUM MONOCLONAL ANTIBODY 12A8 FAB FRAGMENT IN 111; IODINE MONOCLONAL ANTIBODY 12A8 FAB FRAGMENT I 125; RADIOPHARMACEUTICAL AGENT; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL SURFACE; COMPETITIVE INHIBITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; ONCOGENE C KIT; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COPPER RADIOISOTOPES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MICE; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 79954418249     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.10.005     Document Type: Article

References (21)

1. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-kit. Cell Mol Life Sci 2004, 61:2535-2548.
2. Kitamura Y., Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 2004, 61:2924-2931.
3. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96:925-932.
4. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
5. Janeway K.A., Albritton K.H., Van Den Abbeele A.D., D'Amato G.Z., Pedrazzoli P., Siena S., et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer 2009, 52:767-771.
6. Sogawa C., Tsuji A.B., Sudo H., Sugyo A., Yoshida C., Odaka K., et al. C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model. Nucl Med Biol 2010, 37:179-187.
7. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23:1126-1136.
8. Behr T., Becker W., Hannappel E., Goldenberg D.M., Wolf F. Targeting of liver metastases of colorectal cancer with IgG, F(ab')2, and Fab' anti-carcinoembryonic antigen antibodies labeled with 99mTc: the role of metabolism and kinetics. Cancer Res 1995, 55:5777s-5785s.
9. Wahl R.L., Parker C.W., Philpott G.W. Improved radioimaging and tumor localization with monoclonal F(ab')2. J Nucl Med 1983, 24:316-325.
10. Saga T., Endo K., Akiyama T., Sakahara H., Koizumi M., Watanabe Y., et al. Scintigraphic detection of overexpressed c-erbB-2 protooncogene products by a class-switched murine anti-c-erbB-2 protein monoclonal antibody. Cancer Res 1991, 51:990-994.
11. Tsuji A.B., Sogawa C., Sugyo A., Sudo H., Toyohara J., Koizumi M., et al. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. Nucl Med Biol 2009, 36:379-388.
12. Yoshida C., Sogawa C., Tsuji A.B., Sudo H., Sugyo A., Uehara T., et al. Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model. Nucl Med Commun 2010, 31:380-388.
13. Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P.A. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984, 72:77-89.
14. Tsuji A.B., Morita M., Li X.K., Sogawa C., Sudo H., Sugyo A., et al. 18F-FDG PET for semiquantitative evaluation of acute allograft rejection and immunosuppressive therapy efficacy in rat models of liver transplantation. J Nucl Med 2009, 50:827-830.
15. Ferreira C.L., Yapp D.T., Lamsa E., Gleave M., Bensimon C., Jurek P., et al. Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals. Nucl Med Biol 2008, 35:875-882.
16. Jones-Wilson T.M., Deal K.A., Anderson C.J., McCarthy D.W., Kovacs Z., Motekaitis R.J., et al. The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol 1998, 25:523-530.
17. Eiblmaier M., Meyer L.A., Watson M.A., Fracasso P.M., Pike L.J., Anderson C.J., et al. Expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 2008, 49:1472-1479.
18. Tanaka K., Fukase K. PET (positron emission tomography) imaging of biomolecules using metal-DOTA complexes: a new collaborative challenge by chemists, biologists, and physicians for future diagnostics and exploration of in vivo dynamics. Org Biomol Chem 2008, 6:815-828.
19. Cai W., Ebrahimnejad A., Chen K., Cao Q., Li Z.B., Tice D.A., et al. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 2007, 34:2024-2036.
20. Rogers B.E., Anderson C.J., Connett J.M., Guo L.W., Edwards W.B., Sherman E.L., et al. Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. Bioconjug Chem 1996, 7:511-522.
21. Wei L., Butcher C., Miao Y., Gallazzi F., Quinn T.P., Welch M.J., et al. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med 2007, 48:64-72.